[1] Herlitz J. How to improve the cardiac prognosis for diabetes. Diabetes Care 1999;22(Suppl 2):B89-96.

[2] Fagan TC, Deedwania PC. The cardiovascular dys-metabolic syndrome. Am J Med 1998;105(1A): 77S-82S.

[3] UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.

[4] UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.

[5] UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of both mac-rovascular and microvascular complications in type 2 diabetes (UKPDS 39). BMJ 1998;317:713-20.

[6] Haffner SM. Epidemiology of type 2 diabetes: risk factors. Diabetes Care 1998;21(Suppl 3):C3-6.

[7] Tarnow L, Rossing P, Gall M-A, et al. Prevalence of arterial hypertension in diabetic patients before and after the JNC-V. Diabetes Care 1994;17:1247-51.

[8] Hypertension in diabetes study (HDS). I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertension 1993;11:309-17.

[9] Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-91. Hypertension 1995; 25:305-13.

[10] DeStafano F, Ford ES, Newman J, Stevenson JM, Wetterhall SF, Anda RF, et al. Risk factors for coronary heart disease mortality among persons with diabetes. Ann Epidemiol 1993;3:27-34.

[11] Criqui MH. Epidemiology of atherosclerosis: an updated overview. Am J Cardiol 1986;57:18C-23C.

[12] Wilson PW. An epidemiologic perspective of systemic hypertension, ischemic heart disease, and heart failure. Framingham Heart Study. Am J Car-diol 1997;80(9B):3J-8J.

[13] The National High Blood Pressure Education Program Working Group. National High Blood Pressure Education Program Working Group report on hypertension in diabetes. Hypertension 1994;23: 145-58.

[14] Systolic hypertension in Europe trial investigators. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999;340:677-84.

[15] Ritz E, Rychlik I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999; 34:795-808.

[16] Cost effectiveness of intensive treatment of hypertension. Based on presentations by Donald S. Shepard, PhD and Dominic Hodgkin, PhD. Am J Manag Care 1998;4(12 Suppl):S765-9 [discussion S770].

[17] UK Prospective Diabetes Study Group. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. BMJ 1998;12;317(7160):720-6.

[18] Elliott WJ, Weir DR, Black HR. Cost-effectiveness of the lower treatment goal (of JNC VI) for diabetic hypertensive patients. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 2000;8; 160(9):1277-83.

[19] The Sixth Report of The Joint National Committee on Prevention Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-46.

[20] Prencipe M, Casini AR, Santini M, Ferretti C, Scaldaferri N, Culasso F. Prevalence, awareness, treatment and control of hypertension in the elderly: results from a population survey. J Hum Hypertens 2000;14:825-30.

[21] Kjeldsen SE, Dahlof B, Devereux RB, Julius S, de Faire U, Fyhrquist F, et al. Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Losar-tan Intervention For Endpoint. Am J Hypertens 2000;13:899-906.

[22] American Diabetes Association. Position statement: treatment of hypertension in adults with diabetes. 2002;25:571-3.

[23] 1999 Canadian recommendations for the management of hypertension. CMAJ 1999;161(12 Suppl): S1-17.

[24] Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998;339:1285-92.

[25] Wright JM. Choosing a first-line drug in the management of elevated blood pressure: what is the evidence? 2: Beta-blockers. CMAJ 2000;163(2):188-92.

[26] Hansson L, Lindholm LH, Niskanen L, Lanke J, Hendner T, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet 1999;353:611-6.

[27] The Heart Outcomes Prevention Evaluation Study Investigators. Effects of angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342: 145-53.

[28] Galletti F, Strazzullo P, Capaldo B, Carretta R, Fabris F, Ferrara LA, et al. Controlled study of the effect of angiotensin converting enzyme inhibition versus calcium-entry blockade on insulin sensitivity in overweight hypertensive patients: Trandolapril Italian Study (TRIS). J Hypertens 1999;17:439-45.

[29] Buller GK, Perazella M. ACE inhibitor-induced hypoglycaemia. Am J Med 1991;91:104-5.

[30] Heart Outcomes Prevention Evaluation (HOPE) study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355:253-9.

[31] Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? Arch Intern Med 1998;12;158(1):26-32.

[32] Goodfriend TL, Elliott ME, Catt KJ. Drug therapy: angiotensin receptors and their antagonists. N Engl J Med 1996;334:1649-54.

[33] Wright JM. Choosing a first-line drug in the management of elevated blood pressure: what is the evidence? 3: Angiotensin-converting-enzyme, ACE inhibitors. CMAJ 2000;163:293-6.

[34] Piepho RW. Overview of the angiotensin-convert-ing-enzyme inhibitors. Am J Health Syst Pharm 2001;57(Suppl 1):S3-7.

[35] Warner KK, Visconti JA, Tschampel MM. Angio-tensin II receptor blockers in patients with ACE inhibitor-induced angioedema. Ann Pharmacother 2000;34:526-8.

[36] Grossman E. Angiotensin II receptor blockers. Arch Intern Med 2000;160:1905-11.

[37] Bakris GL, Siomos M, Richardson D, Janssen I, Bolton WK, Hebert L, et al. ACE inhibition or an-giotensin receptor blockade: impact on potassium in renal failure. Kidney Int 2000;58:2084-92.

[38] Shah S, Khatri I, Freis ED. Mechanism of antihy-pertensive effect of thiazide diuretics. Am Heart J 1978;95(5):611-8.

[39] Weidmann PO, BoehlenL, deCourtenM. Pathogen-esis and treatment of hypertension associated with diabetes mellitus. Am Heart J 1993;125:1498-513.

[40] Systolic Hypertension in the Elderly Program Cooperative Research Group. Effect of diuretic-based an-tihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996;276:1886-92.

[41] Kostis JB, Berge KG, Davis BR, Hawkins CM, Probstfield J. Effect of atenolol and reserpine on selected events in the systolic hypertension in the elderly program (SHEP). Am J Hypertens 1995; 8(12 Pt 1):1147-53.

[42] Warram J, Laffel LM, Valsania P, et al. Excess mortality associated with diuretic therapy in diabetes mellitus. Arch Intern Med 1991;151:1350-6.

[43] David S, Siscovick TE, Raghunathan BM, Psaty TD, Koepsell KG, Wicklund XL, et al. Diuretic Therapy for Hypertension and the Risk of Primary Cardiac Arrest. N Engl J Med 1994; 330:1852-7.

[44] Zuanetti G, Latini R. Impact of pharmacological treatment on mortality after myocardial infarction in diabetic patients. J Diabet Complications 1997; 11:131-6.

[45] Gress TW, Nieto J, Shahar I, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. For the atherosclerosis risk in communities study. N Engl J Med 2000;342: 905-12.

[46] Veterans Administration Cooperative Study Group on Antihypertensive Agents. Propranolol or hydro-chlorothiazide alone for the initial treatment of hypertension. IV. Effect on plasma glucose and glucose tolerance. Hypertension 1985;7:1008-16.

[47] Ravid M, Brosh D, Levi Z, Bar-Dayan Y, et al. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1998;128:982-8.

[48] Deacon SP, Barnett D. Comparison of atenolol and propranolol during insulin-induced hypoglycaemia. BMJ 1976;2:272-3.

[49] Kerr D, Macdonald IA, Heller SR, et al. Beta-adrenoceptor blockade and hypoglycaema. Br J Clin Pharmacol 1990;29:685-93.

[50] Hirsch IB, Boyle PJ, Craft S, Cryer PE. Higher glycemic thresholds for symptoms during beta-adrenergic blockade in IDDM. Diabetes 1991; 40(9):1177-86.

[51] Lyngsoe J, Sorensen M, Sjostrand H, et al. The effect of sustained release verapamil on glucose metabolism in patients with NIDDM. Drugs 1992;1: 85-7.

[52] HanssonL,ZanchettiA,CarruthersSG,etal. Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998;351:1755-62.

[53] Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension. N Engl J Med 1998;338:645-52.

[54] Tatti P, Pahor M, Byington R. Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998;21: 597-603.

[55] Messerli FH, Oparil S, Feng Z. Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (bena-zepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension. Am J Cardiol 2000;86:1182-7.

[56] Lithell HO. Hyperinsulinemia, insulin resistance, and the treatment of hypertension. Am J Hypertens 1996;9:150S-4S.

[57] Andersen P, Seljeflot I, Herzog A. Effects of doxazosin and atenolol on atherothrombogenic risk profile in hypertensive middle-age men. J Cardiovasc Pharmacol 1998;31:677-83.

[58] The ALLHAT officers and coordinators for the ALLHAT Collaborative Research Group. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone. JAMA 2000;283:1967-75.

[59] Bauer JH, Jones LB, Gaddy P. Effects of prazosin therapy on blood pressure, renal function, and body fluid composition. Arch Intern Med 1984;114: 1196-200.

[60] Leenen FHH, Smith DL, Faraks RM, Reeves RA, Marquez-Julio A. Vasodilators and regression ofleft ventricular hypertrophy: hydralazine versus prazo-sin in hypertensive patients. Am J Med 1987;82: 969-78.

[61] Liebson PR, Grandits GA, Dianzumba S. Comparison of 5 antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the treatment of mild hypertension study. Circulation 1995; 91:698-706.

[62] Gottdiener JS, Reda DJ, Massie BM. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. Circulation 1997;95: 2007-14.

[63] Liao Y, Husain A. The chymase-angiotensin system in humans: biochemistry, molecular biology and potential role in cardiovascular diseases. Can J Cardiol 1995;11(Suppl F):13F-9F.

[64] Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbu-minuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321(7274):1440-4.

[65] Lacourciere Y, Belanger A, Godin C, Halle JP, Ross S, Wright N, et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int 2000;58(2):762-9.

[66] Pohl M, Cooper M, Ulrey J, Pauls J, Rohse R. Safety and efficacy of irbesartan in hypertensive patients with type 2 diabetes and proteinuria [abstract]. Am J Hypertens 1997;10:105A.

[67] Lindholm LH, Hansson L, Ekbom T, Dahlof B, Lanke J, Linjer E, et al. Comparison of antihyper-tensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group. J Hypertens 2000;18(11):1671-5.

[68] Hansson L, Lindholm LH, Ekbom T, Dahlof B, Lanke J, Schersten B, et al, for the STOP-Hyperten-sion-2 study group. Randomised trial ofold and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:1751-6.

[69] Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, et al, for the NORDIL Study Group. Randomised trial of effects of calcium antagonists compared with diuretics and ß-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000;356:359-65.

[70] Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000;356:366-72.

[71] Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329: 1456-62.

[72] Ravid M, Broth D, Levi Z, Bar-Dayan Y, et al. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1998;128:982-8.

[73] Mogensen CE. Renoprotective role of ACE inhibitors in diabetic nephropathy. Br Heart J 1994;72(3 Suppl):S38-45.

[74] Ruddy M. Angiotensin II receptor blockade in diabetic nephropathy. Am J Hypertens 2002;15:466.

[75] Estacio RO, Jeffers BW, Gifford N, Dchrier RW. Effect of blood pressure control on diabetic micro-vascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000;23(Suppl 2): B54-64.

[76] Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease: the Modification of Diet in Renal Disease Study. Ann Intern Med 1995;123:754-62.

[77] Lazarus JM, Bourgoignie JJ, Buckalew VM, et al, for the Modification of Diet in Renal Disease Study Group. Achievement and safety of low blood pressure goal in chronic renal disease: the Modification of Diet in Renal Disease Study Group. Hypertension 1997;29:641-50.

[78] Luscher TF, Waeber B. Efficacy and safety of various combination therapies based on a calcium antagonist in essential hypertension: results of a placebo-controlled randomized trial. J Cardiovasc Pharmacol 1993;21(2):305-9.

[79] Pittrow DB, Antlsperger A, Welzel D, Wambach G, Schardt W, Weidinger G. Evaluation of the efficacy and tolerability of a low-dose combination of isradi-pine and spirapril in the first-line treatment of mild to moderate essential hypertension. Cardiovasc Drugs Ther 1997;11(5):619-27.

[80] Plat F, Saini R. Management of hypertension: the role of combination therapy. Am J Hypertens 1997;10(10 Pt 2):262S-71S.

[81] Corcoran JS, Perkins JE, Hoffbrand BI, Yudkin JS. Treating hypertension in non-insulin-dependent diabetes: a comparison of atenolol, nifedipine, and cap-topril combined with bendrofluazide. Diabet Med 1987;4(2):164-8.

[82] Shigihara T, Sato A, Hayashi K, Saruta T. Effect of combination therapy of angiotensin-converting enzyme inhibitor plus calcium channel blocker on urinary albumin excretion in hypertensive micro-albuminuric patients with type II diabetes. Hyper-tens Res 2000;23(3):219-26.

[83] Bakris GL, Weir MR, DeQuattro V, McMahon FG. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropa-thy. Kidney Int 1998;54(4):1283-9.

[84] Souviron Rodriguez A, Martinez Morillo M. Captopril + hydrochlorothiazide versus capto-pril + nifedipine in the treatment of arterial hypertension in diabetes mellitus type II [abstract]. Rev Esp Cardiol 1992;45(7):432-7 [in Spanish].

[85] Schneider M, Lerch M, Papiri M, Buechel P, Boehlen L, Shaw S, et al. Metabolic neutrality of combined verapamil-trandolapril treatment in contrast to beta-blocker-low-dose chlortali done treatment in hypertensive type 2 diabetes. J Hypertens 1993;14(5):669-77.

[86] Sheinfeld GR, Bakris GL. Benefits of combination angiotensin-converting enzyme inhibitor and calcium antagonist therapy for diabetic patients. Am J Hypertens 1999;12(8)(Pt 2):80S-5S.

[87] Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993; 16:434-44.

[88] Sniderman A, Michel C, Racine N. Heart disease in patients with diabetes mellitus. J Clin Epidemiol 1992;45:1357-70.


Cardiol Clin 23 (2005) 153-164


Diabetes 2

Diabetes 2

Diabetes is a disease that affects the way your body uses food. Normally, your body converts sugars, starches and other foods into a form of sugar called glucose. Your body uses glucose for fuel. The cells receive the glucose through the bloodstream. They then use insulin a hormone made by the pancreas to absorb the glucose, convert it into energy, and either use it or store it for later use. Learn more...

Get My Free Ebook

Post a comment